Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial.

Schmainda KM, Prah MA, Zhang Z, Snyder BS, Rand SD, Jensen TR, Barboriak DP, Boxerman JL.

AJNR Am J Neuroradiol. 2019 Jul;40(7):1132-1139. doi: 10.3174/ajnr.A6110. Epub 2019 Jun 27.

PMID:
31248863
2.

Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors.

Schmainda KM, Prah MA, Hu LS, Quarles CC, Semmineh N, Rand SD, Connelly JM, Anderies B, Zhou Y, Liu Y, Logan B, Stokes A, Baird G, Boxerman JL.

AJNR Am J Neuroradiol. 2019 Apr;40(4):626-633. doi: 10.3174/ajnr.A6015. Epub 2019 Mar 28.

3.

Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO).

Bell LC, Semmineh N, An H, Eldeniz C, Wahl R, Schmainda KM, Prah MA, Erickson BJ, Korfiatis P, Wu C, Sorace AG, Yankeelov TE, Rutledge N, Chenevert TL, Malyarenko D, Liu Y, Brenner A, Hu LS, Zhou Y, Boxerman JL, Yen YF, Kalpathy-Cramer J, Beers AL, Muzi M, Madhuranthakam AJ, Pinho M, Johnson B, Quarles CC.

Tomography. 2019 Mar;5(1):110-117. doi: 10.18383/j.tom.2018.00041.

4.

The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge, Part II.

Huang W, Chen Y, Fedorov A, Li X, Jajamovich GH, Malyarenko DI, Aryal MP, LaViolette PS, Oborski MJ, O'Sullivan F, Abramson RG, Jafari-Khouzani K, Afzal A, Tudorica A, Moloney B, Gupta SN, Besa C, Kalpathy-Cramer J, Mountz JM, Laymon CM, Muzi M, Kinahan PE, Schmainda K, Cao Y, Chenevert TL, Taouli B, Yankeelov TE, Fennessy F, Li X.

Tomography. 2019 Mar;5(1):99-109. doi: 10.18383/j.tom.2018.00027.

5.

Irradiation of pediatric glioblastoma cells promotes radioresistance and enhances glioma malignancy via genome-wide transcriptome changes.

Alhajala HS, Nguyen HS, Shabani S, Best B, Kaushal M, Al-Gizawiy MM, Erin Ahn EY, Knipstein JA, Mirza S, Schmainda KM, Chitambar CR, Doan NB.

Oncotarget. 2018 Sep 25;9(75):34122-34131. doi: 10.18632/oncotarget.26137. eCollection 2018 Sep 25.

6.

ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.

Ratai EM, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, Richards T, Kim D, Andronesi OC, Mintz A, Kostakoglu L, Prah M, Ellingson B, Schmainda K, Sorensen G, Barboriak D, Mankoff D, Gerstner ER; ACRIN 6684 trial group.

PLoS One. 2018 Jun 14;13(6):e0198548. doi: 10.1371/journal.pone.0198548. eCollection 2018.

7.

Identification of radiation responsive genes and transcriptome profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model.

Doan NB, Nguyen HS, Alhajala HS, Jaber B, Al-Gizawiy MM, Ahn EE, Mueller WM, Chitambar CR, Mirza SP, Schmainda KM.

Oncotarget. 2018 May 4;9(34):23532-23542. doi: 10.18632/oncotarget.25247. eCollection 2018 May 4.

8.

Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project.

Schmainda KM, Prah MA, Rand SD, Liu Y, Logan B, Muzi M, Rane SD, Da X, Yen YF, Kalpathy-Cramer J, Chenevert TL, Hoff B, Ross B, Cao Y, Aryal MP, Erickson B, Korfiatis P, Dondlinger T, Bell L, Hu L, Kinahan PE, Quarles CC.

AJNR Am J Neuroradiol. 2018 Jun;39(6):1008-1016. doi: 10.3174/ajnr.A5675. Epub 2018 May 24.

9.

Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase.

Chitambar CR, Al-Gizawiy MM, Alhajala HS, Pechman KR, Wereley JP, Wujek R, Clark PA, Kuo JS, Antholine WE, Schmainda KM.

Mol Cancer Ther. 2018 Jun;17(6):1240-1250. doi: 10.1158/1535-7163.MCT-17-1009. Epub 2018 Mar 28.

10.

Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency.

Doan NB, Alhajala H, Al-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, Cochran EJ, Chitambar CR, Clark P, Kuo J, Schmainda KM, Mirza SP.

Oncotarget. 2017 Nov 7;8(68):112662-112674. doi: 10.18632/oncotarget.22637. eCollection 2017 Dec 22.

11.

Toward uniform implementation of parametric map Digital Imaging and Communication in Medicine standard in multisite quantitative diffusion imaging studies.

Malyarenko D, Fedorov A, Bell L, Prah M, Hectors S, Arlinghaus L, Muzi M, Solaiyappan M, Jacobs M, Fung M, Shukla-Dave A, McManus K, Boss M, Taouli B, Yankeelov TE, Quarles CC, Schmainda K, Chenevert TL, Newitt DC.

J Med Imaging (Bellingham). 2018 Jan;5(1):011006. doi: 10.1117/1.JMI.5.1.011006. Epub 2017 Oct 30.

12.

Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network.

Newitt DC, Malyarenko D, Chenevert TL, Quarles CC, Bell L, Fedorov A, Fennessy F, Jacobs MA, Solaiyappan M, Hectors S, Taouli B, Muzi M, Kinahan PE, Schmainda KM, Prah MA, Taber EN, Kroenke C, Huang W, Arlinghaus LR, Yankeelov TE, Cao Y, Aryal M, Yen YF, Kalpathy-Cramer J, Shukla-Dave A, Fung M, Liang J, Boss M, Hylton N.

J Med Imaging (Bellingham). 2018 Jan;5(1):011003. doi: 10.1117/1.JMI.5.1.011003. Epub 2017 Oct 10.

13.

Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.

Prah MA, Al-Gizawiy MM, Mueller WM, Cochran EJ, Hoffmann RG, Connelly JM, Schmainda KM.

J Neurooncol. 2018 Jan;136(1):13-21. doi: 10.1007/s11060-017-2617-3. Epub 2017 Sep 12.

14.

Acid ceramidase confers radioresistance to glioblastoma cells.

Doan NB, Nguyen HS, Al-Gizawiy MM, Mueller WM, Sabbadini RA, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP.

Oncol Rep. 2017 Oct;38(4):1932-1940. doi: 10.3892/or.2017.5855. Epub 2017 Jul 28.

15.

Optimization of DSC MRI Echo Times for CBV Measurements Using Error Analysis in a Pilot Study of High-Grade Gliomas.

Bell LC, Does MD, Stokes AM, Baxter LC, Schmainda KM, Dueck AC, Quarles CC.

AJNR Am J Neuroradiol. 2017 Sep;38(9):1710-1715. doi: 10.3174/ajnr.A5295. Epub 2017 Jul 6.

16.

Acid ceramidase is a novel drug target for pediatric brain tumors.

Doan NB, Nguyen HS, Montoure A, Al-Gizawiy MM, Mueller WM, Kurpad S, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP.

Oncotarget. 2017 Apr 11;8(15):24753-24761. doi: 10.18632/oncotarget.15800.

17.
18.

Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before Therapy.

McGarry SD, Hurrell SL, Kaczmarowski AL, Cochran EJ, Connelly J, Rand SD, Schmainda KM, LaViolette PS.

Tomography. 2016 Sep;2(3):223-228.

19.

Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.

Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS.

AJNR Am J Neuroradiol. 2016 Dec;37(12):2201-2208. Epub 2016 Aug 4.

20.

The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge.

Huang W, Chen Y, Fedorov A, Li X, Jajamovich GH, Malyarenko DI, Aryal MP, LaViolette PS, Oborski MJ, O'Sullivan F, Abramson RG, Jafari-Khouzani K, Afzal A, Tudorica A, Moloney B, Gupta SN, Besa C, Kalpathy-Cramer J, Mountz JM, Laymon CM, Muzi M, Schmainda K, Cao Y, Chenevert TL, Taouli B, Yankeelov TE, Fennessy F, Li X.

Tomography. 2016 Mar;2(1):56-66.

21.

ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.

Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak DP, Mankoff DA; ACRIN 6684 Trial Group.

Clin Cancer Res. 2016 Oct 15;22(20):5079-5086. Epub 2016 May 16.

22.

Location of brain tumor intersecting white matter tracts predicts patient prognosis.

Mickevicius NJ, Carle AB, Bluemel T, Santarriaga S, Schloemer F, Shumate D, Connelly J, Schmainda KM, LaViolette PS.

J Neurooncol. 2015 Nov;125(2):393-400. doi: 10.1007/s11060-015-1928-5. Epub 2015 Sep 16.

23.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

Boxerman JL, Schmainda KM, Zhang Z, Barboriak DP.

Neuro Oncol. 2015 Nov;17(11):1538-9. doi: 10.1093/neuonc/nov163. Epub 2015 Sep 11. No abstract available.

24.

Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.

Prah MA, Stufflebeam SM, Paulson ES, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Barboriak DP, Rosen BR, Schmainda KM.

AJNR Am J Neuroradiol. 2015 Sep;36(9):1654-61. doi: 10.3174/ajnr.A4374. Epub 2015 Jun 11.

25.

Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients.

Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjørnerud A, Vangel MG, Gerstner ER, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM.

Transl Oncol. 2015 Jun;8(3):137-46. doi: 10.1016/j.tranon.2015.03.002.

26.

Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.

Schmainda KM, Zhang Z, Prah M, Snyder BS, Gilbert MR, Sorensen AG, Barboriak DP, Boxerman JL.

Neuro Oncol. 2015 Aug;17(8):1148-56. doi: 10.1093/neuonc/nou364. Epub 2015 Feb 2.

27.

Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma.

LaViolette PS, Mickevicius NJ, Cochran EJ, Rand SD, Connelly J, Bovi JA, Malkin MG, Mueller WM, Schmainda KM.

Neuro Oncol. 2014 Dec;16(12):1599-606. doi: 10.1093/neuonc/nou142. Epub 2014 Jul 24.

28.

Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics.

Heroux MS, Chesnik MA, Halligan BD, Al-Gizawiy M, Connelly JM, Mueller WM, Rand SD, Cochran EJ, LaViolette PS, Malkin MG, Schmainda KM, Mirza SP.

Physiol Genomics. 2014 Jul 1;46(13):467-81. doi: 10.1152/physiolgenomics.00034.2014. Epub 2014 May 6.

29.

The effect of low b-values on the intravoxel incoherent motion derived pseudodiffusion parameter in liver.

Cohen AD, Schieke MC, Hohenwalter MD, Schmainda KM.

Magn Reson Med. 2015 Jan;73(1):306-11. doi: 10.1002/mrm.25109. Epub 2014 Jan 29.

30.

Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG.

Neuro Oncol. 2014 Jun;16(6):880-8. doi: 10.1093/neuonc/not216. Epub 2014 Jan 15.

31.

Effect of contrast leakage on the detection of abnormal brain tumor vasculature in high-grade glioma.

LaViolette PS, Daun MK, Paulson ES, Schmainda KM.

J Neurooncol. 2014 Feb;116(3):543-549. doi: 10.1007/s11060-013-1318-9. Epub 2013 Nov 29.

32.

Diffusion-weighted MRI as a biomarker for treatment response in glioma.

Schmainda KM.

CNS Oncol. 2012 Nov;1(2):169-80. Review.

33.

Multiphasic modification of intrinsic functional connectivity of the rat brain during increasing levels of propofol.

Liu X, Pillay S, Li R, Vizuete JA, Pechman KR, Schmainda KM, Hudetz AG.

Neuroimage. 2013 Dec;83:581-92. doi: 10.1016/j.neuroimage.2013.07.003. Epub 2013 Jul 10.

34.

The effect of pulse sequence parameters and contrast agent dose on percentage signal recovery in DSC-MRI: implications for clinical applications.

Boxerman JL, Paulson ES, Prah MA, Schmainda KM.

AJNR Am J Neuroradiol. 2013 Jul;34(7):1364-9. doi: 10.3174/ajnr.A3477. Epub 2013 Feb 14.

35.

Effects of perfusion on diffusion changes in human brain tumors.

Cohen AD, LaViolette PS, Prah M, Connelly J, Malkin MG, Rand SD, Mueller WM, Schmainda KM.

J Magn Reson Imaging. 2013 Oct;38(4):868-75. doi: 10.1002/jmri.24042. Epub 2013 Feb 6.

36.

Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.

LaViolette PS, Cohen AD, Prah MA, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM.

Neuro Oncol. 2013 Apr;15(4):442-50. doi: 10.1093/neuonc/nos323. Epub 2013 Feb 3.

37.

Presumed hydrogen sulfide-mediated neurotoxicity after streptococcus anginosus group meningitis.

Verma S, Landisch R, Quirk B, Schmainda K, Prah M, Whelan HT, Willoughby RE Jr.

Pediatr Infect Dis J. 2013 Feb;32(2):189-91. doi: 10.1097/INF.0b013e3182748fe9.

38.

The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard.

Boxerman JL, Prah DE, Paulson ES, Machan JT, Bedekar D, Schmainda KM.

AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7. doi: 10.3174/ajnr.A2934. Epub 2012 Feb 9.

39.

Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume.

Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Schmainda KM.

Magn Reson Med. 2012 Oct;68(4):1266-72. doi: 10.1002/mrm.23315. Epub 2011 Dec 28.

40.

Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.

Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB.

Neuro Oncol. 2011 Oct;13(10):1151-61. doi: 10.1093/neuonc/nor079. Epub 2011 Aug 19.

41.

Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume.

Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Hoffmann RG, Schmainda KM.

J Neurooncol. 2011 Nov;105(2):233-9. doi: 10.1007/s11060-011-0591-8. Epub 2011 Apr 30.

42.

Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI.

Ellingson BM, LaViolette PS, Rand SD, Malkin MG, Connelly JM, Mueller WM, Prost RW, Schmainda KM.

Magn Reson Med. 2011 Apr;65(4):1131-43. doi: 10.1002/mrm.22688. Epub 2010 Nov 30.

43.

3D visualization of subdural electrode shift as measured at craniotomy reopening.

LaViolette PS, Rand SD, Ellingson BM, Raghavan M, Lew SM, Schmainda KM, Mueller W.

Epilepsy Res. 2011 Mar;94(1-2):102-9. doi: 10.1016/j.eplepsyres.2011.01.011. Epub 2011 Feb 18.

44.

Multimodality imaging of abnormal vascular perfusion and morphology in preclinical 9L gliosarcoma model.

Darpolor MM, Molthen RC, Schmainda KM.

PLoS One. 2011 Jan 31;6(1):e16621. doi: 10.1371/journal.pone.0016621.

45.

Three-dimensional visualization of subdural electrodes for presurgical planning.

LaViolette PS, Rand SD, Raghavan M, Ellingson BM, Schmainda KM, Mueller W.

Neurosurgery. 2011 Mar;68(1 Suppl Operative):152-60; discussion 160-1. doi: 10.1227/NEU.0b013e31820783ba.

46.

Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons.

Bedekar D, Jensen T, Schmainda KM.

Magn Reson Med. 2010 Sep;64(3):907-13. doi: 10.1002/mrm.22445.

47.

Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas.

Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM.

J Neurooncol. 2011 Mar;102(1):95-103. doi: 10.1007/s11060-010-0293-7. Epub 2010 Aug 27.

48.

A simple method for rectified noise floor suppression: Phase-corrected real data reconstruction with application to diffusion-weighted imaging.

Prah DE, Paulson ES, Nencka AS, Schmainda KM.

Magn Reson Med. 2010 Aug;64(2):418-29. doi: 10.1002/mrm.22407.

49.

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity.

Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedekar DP, Schmainda KM.

J Magn Reson Imaging. 2010 Mar;31(3):538-48. doi: 10.1002/jmri.22068.

50.

Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri.

Ellingson BM, Rand SD, Malkin MG, Schmainda KM.

J Neurooncol. 2010 May;97(3):419-23. doi: 10.1007/s11060-009-0018-y. Epub 2009 Oct 8.

Supplemental Content

Loading ...
Support Center